Evidence map›Paper›PMID 37195298›Full record

ArticleJournal of cancer research and clinical oncology2023

Sclerosing mesenteritis following immune checkpoint inhibitor therapy.

Andrew G Kuang, Gabriel Sperling, Tom Z Liang, Yang Lu, Dongfeng Tan, Kathryn Bollin, Douglas B Johnson, Joanna-Grace M Manzano, Malek Shatila, Anusha S Thomas and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Observational
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Andrew G KuangDepartment of Medicine, Baylor College of Medicine, Houston, TX, USA.
Gabriel SperlingThe University of Texas Medical Branch John Sealy School of Medicine, Galveston, TX, USA.
Tom Z LiangDivision of Pathology/Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yang LuDepartment of Nuclear Medicine, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Dongfeng TanDivision of Pathology/Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kathryn BollinDivision of Hematology and Oncology, Scripps MD Anderson Cancer Center, La Jolla, CA, USA.
Douglas B JohnsonDivision of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Joanna-Grace M ManzanoDepartment of Hospital Medicine, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Malek ShatilaDepartment of Gastroenterology, Hepatology, & Nutrition, Division of Internal Medicine, Unit 1466, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Anusha S ThomasDepartment of Gastroenterology, Hepatology, & Nutrition, Division of Internal Medicine, Unit 1466, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
John A ThompsonDivison of Medical Oncology, University of Washington, Seattle, WA, USA.
Hao Chi ZhangDepartment of Gastroenterology, Hepatology, & Nutrition, Division of Internal Medicine, Unit 1466, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Yinghong WangDepartment of Gastroenterology, Hepatology, & Nutrition, Division of Internal Medicine, Unit 1466, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. ywang59@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USBaylor College of Medicine · USJohn Sealy Hospital · USScripps MD Anderson Cancer Center · USUniversity of Washington Medical Center · USVanderbilt University Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSclerosing mesenteritis (SM), a fibroinflammatory process of the mesentery, can rarely occur after immune checkpoint inhibitor (ICI) therapy; however, its clinical significance and optimal management are unclear. We aimed to assess the characteristics and disease course of patients who developed SM following ICI therapy at a single tertiary cancer center.

methodsWe retrospectively identified 12 eligible adult cancer patients between 05/2011 and 05/2022. Patients' clinical data were evaluated and summarized.

resultsThe median patient age was 71.5 years. The most common cancer types were gastrointestinal, hematologic, and skin. Eight patients (67%) received anti-PD-1/L1 monotherapy, 2 (17%) received anti-CTLA-4 monotherapy, and 2 (17%) received combination therapy. SM occurred after a median duration of 8.6 months from the first ICI dose. Most patients (75%) were asymptomatic on diagnosis. Three patients (25%) reported abdominal pain, nausea, and fever and received inpatient care and corticosteroid treatment with symptom resolution. No patients experienced SM recurrence after the completion of corticosteroids. Seven patients (58%) experienced resolution of SM on imaging. Seven patients (58%) resumed ICI therapy after the diagnosis of SM.

conclusionsSM represents an immune-related adverse event that may occur after initiation of ICI therapy. The clinical significance and optimal management of SM following ICI therapy remains uncertain. While most cases were asymptomatic and did not require active management or ICI termination, medical intervention was needed in select symptomatic cases. Further large-scale studies are needed to clarify the association of SM with ICI therapy.

Indexed as

Immune Checkpoint InhibitorsMediastinitisNeoplasmsSclerosisAdrenal Cortex HormonesAgedFemaleHumansMaleMiddle AgedRetrospective StudiesAdrenal Cortex HormonesImmune Checkpoint InhibitorsAnti-CTLA-4Anti-PD-1/L1Immune checkpoint inhibitorImmune-related adverse eventSclerosing mesenteritis

Identifiers

PMID37195298
PMCPMC11796806
OpenAlexW4376871109

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.